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A B S T R A C T
We investigated whether morphine and its pro-drug codeine are substrates of the highly genetically
polymorphic organic cation transporter OCT1 and whether OCT1 polymorphisms may affect morphine
and codeine pharmacokinetics in humans.
Morphine showed low transporter-independent membrane permeability (0.5  106 cm/s). Mor-
phine uptake was increased up to 4-fold in HEK293 cells overexpressing human OCT1. The increase was
concentration-dependent and followed Michaelis-Menten kinetics (KM = 3.4 mM, VMAX = 27 pmol/min/
mg protein). OCT1-mediated morphine uptake was abolished by common loss-of-function polymor-
phisms in the OCT1 gene and was strongly inhibited by drug-drug interactions with irinotecan,
verapamil and ondansetron. Morphine uptake in primary human hepatocytes was strongly reduced by
MPP+, an inhibitor of organic cation transporters, and morphine was not a substrate of OCT3, the other
organic cation transporter expressed in human hepatocytes. In concordance with the in vitro data,
morphine plasma concentrations in healthy volunteers were signiﬁcantly dependent on OCT1
polymorphisms. After codeine administration, the mean AUC of morphine was 56% higher in carriers
of loss-of-function OCT1 polymorphisms compared to non-carriers (P = 0.005). The difference remained
signiﬁcant after adjustment for CYP2D6 genotype (P = 0.03). Codeine itself had high transporter-
independent membrane permeability (8.2  106 cm/s). Codeine uptake in HEK293 cells was not
affected by OCT1 overexpression and OCT1 polymorphisms did not affect codeine AUCs.
In conclusion, OCT1 plays an important role in the hepatocellular uptake of morphine. Carriers of loss-
of-function OCT1 polymorphisms may be at higher risk of adverse effects after codeine administration,
especially if they are also ultra-rapid CYP2D6 metabolizers.
 2013 The Authors. Published by Elsevier Inc. 
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Morphine and codeine are natural opioids used to treat
moderate to severe pain [1,2]. In humans, codeine is metabolized
to morphine by CYP2D6. Codeine is regarded as a pro-drug whose
opioid activity is mostly executed via its metabolite morphine
[3–5].       
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Open access under CC BY-NC-NDSevere respiratory depression is observed after morphine
overdose or in the case of extremely high metabolizing rates of
codeine to morphine [6,7]. Ampliﬁcation of the CYP2D6 gene was
assumed to be the cause of some cases of death from respiratory
depression after codeine administration [8–13]. Therefore, geno-
typing of CYP2D6 prior to codeine administration has been
recommended and a warning is issued in the ofﬁcial FDA drug
label [14,15]. However, CYP2D6 genotyping alone can only partially
predict high plasma concentrations of morphine after codeine
administration [16,17].
Both morphine and codeine undergo extensive hepatic
metabolism before renal elimination. The majority of morphine
is eliminated in the urine as morphine 3-glucuronide or morphine
6-glucuronide [18]. Codeine is mostly eliminated as codeine 6-
glucuronide, and less than 10% as morphine or its glucuronides
[19]. Glucuronidation of codeine and morphine in the liver is license.
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known how morphine and codeine enter the liver.
Morphine and codeine are weak bases that under physiological
conditions coexist in a protonated and a non-protonated form. The
non-protonated forms of morphine and codeine may penetrate
cellular membranes by passive diffusion. However, morphine, in
contrast to codeine and some other opioids, has only limited
membrane permeability by diffusion [21]. More than 85% of
morphine and codeine are positively charged at pH of 7.4. It
remains unclear whether these protonated forms may be taken up
into the liver by organic cation transporters expressed in the
sinusoidal membrane of hepatocytes.
The organic cation transporter isoform 1 (OCT1, alternative
name SLC22A1) is the major organic cation transporter expressed
in the sinusoidal membrane of the human hepatocytes [22]. OCT1
is highly genetically variable. Five common loss-of-function OCT1
polymorphisms are known in Caucasians: Arg61Cys, Cys88Arg,
Gly401Ser, Gly465Arg, and a Met420 deletion [23,24]. Nine
percent of Caucasians are compound homozygous carriers of
these ﬁve polymorphisms and lack substantial OCT1 activity. An
additional 40% are heterozygous carriers and have only one active
OCT1 allele. Loss of OCT1 function was shown to limit the uptake
and activity of drugs acting on, or metabolized by the human liver
[25–27]. Furthermore, morphine and codeine have been previously
shown to inhibit OCT1-mediated uptake [28], indicating that both
drugs may be potential OCT1 substrates.
Here we analysed whether morphine and codeine are
substrates of OCT1, whether hepatic uptake of morphine and
codeine depends on OCT1, and whether common loss-of-function
polymorphisms in OCT1 may affect the pharmacokinetics of
morphine and codeine after codeine administration in humans.
2. Materials and methods
2.1. Materials
The radiolabeled chemicals 14C-codeine, 14C-morphine, 3H-
morphine and 3H-MPP+ were obtained from Hartmann Analytic
(Braunschweig, Germany). The speciﬁc activities of the 14C-labled
substances was 55 Ci/mol, and that of the 3H-labled substances
was 80 Ci/mmol. All non-radiolabeled chemicals were obtained
from Sigma-Aldrich (Taufkirchen, Germany). Generation and
characterization of the HEK293 cells overexpressing human
OCT1 used in this study has been described in detail [29].
HEK293 cells overexpressing human OCT3 were a kind gift from
Drs. Koepsell and Gorboulev (University of Wu¨rzburg, Germany).
Cryopreserved human hepatocytes and all cell-culture media and
additives were obtained from Gibco (Life Technologies, Darmstadt,
Germany). The cryopreserved human hepatocytes were from a
single male Caucasian with two active OCT1 alleles. A post-mortem
human liver RNA sample of a single male donor, age 69, was
obtained from Ambion (Life Technologies). The reagents used in
the RT-qPCR were obtained from Life Technologies except for the
random hexanucleotide primers (Roche, Mannheim, Germany)
and recombinant human placenta RNase inhibitor (Affymetrix,
High Wycombe, United Kingdom).
2.2. Parallel artiﬁcial membrane permeability assay
The parallel artiﬁcial membrane permeability assays were
performed using pre-coated PAMPA 96-well plates (BD Bios-
ciences, Heidelberg, Germany) according to the manufacturer’s
instructions. The assays were performed using radiolabeled
morphine or codeine dissolved in phosphate-buffer saline (pH
7.4). The plates were incubated for 5 h at room temperature
without shaking. The starting and ﬁnal concentrations of morphineand codeine were determined using liquid scintillation counting.
Membrane permeability Pe was calculated as follows:
Pe ¼ ln½1  CA  ðVD þ VAÞ=ðCD  VD þ CA  VAÞ½A  ð1=VD þ 1=VAÞ  t
where CD and CA are the end concentrations and VD and VA are the
volumes in the donor and the acceptor wells, respectively. A is the
membrane surface area, and t is the incubation time. VD, VA, A, and t
were constant in all experiments and were 0.3 ml, 0.2 ml, 0.3 cm2
and 18,000 s, respectively.
2.3. Cellular uptake measurements
HEK293 cells (6  105) were plated in a single well of 12 -well
plates pre-coated with poly-D-lysine (1–4 kDa; Sigma–Aldrich).
The cells were incubated for three days to reach complete
conﬂuence. All uptake measurements were performed at pH 7.4.
The cells were washed with 1 ml 37 8C Hank’s Buffered Salt
Solution (HBSS, Life Technology). The reaction was started by
adding 400 ml 37 8C HBSS containing the radiolabeled substrate
and stopped after exactly 2 min by adding 2 ml ice-cold HBSS. The
cells were washed twice with 2 ml ice-cold HBSS and lysed in
500 ml 0.1 N NaOH solution containing 0.1% SDS. The intracellular
accumulated substrate was quantiﬁed in a liquid scintillation
counter (Beckman LS5000TD from Beckman Coulter, Krefeld,
Germany) after supplementing 400 ml of the cell lysates with 8 ml
Aquasafe 500+ liquid scintillator (Zinsser Analytics, Frankfurt-am-
Main, Germany), and normalized to the total protein amount
determined by the BCA-method [30]. Due to its low speciﬁc
activity, 14C-morphine was used for uptake measurements in the
micromolar range, while 3H-morphine, which has higher speciﬁc
activity, was used for uptake measurements in the nanomolar
range.
For measuring the uptake in human hepatocytes, an aliquot of
cryopreserved hepatocytes was rapidly thawed in a 37 8C water
bath, poured into 47 ml cryopreserved hepatocyte recovery
medium (CHRM, Life Technologies) and pelleted by centrifugation
(100  g, 10 min, 4 8C). The cells were re-suspended in cryopre-
served hepatocyte plating medium (CHPM, Life Technologies) and
4  105 cells were plated in a single well of a 24-well plate coated
with collagen I (Life Technologies). The cells were left for 3 h to
attach and the uptake experiments were performed as described
above.
The Michaelis constant (KM) and the maximal transport rates
(VMAX) were determined using linear regression after Lineweaver-
Burk transformation. The regression analyses were performed
using SigmaPlot 11 (Systat Software Inc., Erkrath, Germany).
2.4. Inhibition experiments
OCT1-overexpressing HEK293 cells were incubated with 5 nM
3H-morphine for 2 min in the absence or in the presence of
increasing concentrations of the inhibitor. Control HEK293 cells
stably transfected with the empty pcDNA5 plasmid were also
treated with 3H-morphine without inhibitor to account for OCT1-
independent morphine uptake. The cells were lysed and the
amount of intracellular morphine was quantiﬁed as described in
methods Section 2.3.
The half-maximal inhibition constants (IC50) were determined
by ﬁtting the data into the equation:
YðCÞ ¼ Ymin þ
ðYmax  YminÞ
ð1 þ ðC=IC50ÞHÞ
wh
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an inhibitor concentration of C, Ymin and Ymax are the maximal and
minimal morphine uptakes, respectively, and H is the Hill slope.
The maximal plasma concentration of the unbound drug (CMAX
Unb) was calculated by multiplying the CMAX by the fraction
unbound in plasma. If not available for the given dose CMAX was
extrapolated assuming linear pharmacokinetics for the drugs
analysed. The maximal unbound plasma concentration in the
portal vein (CMAX Port. Unb.) was calculated according to the
following equation described by Ahlin et al. and Ito et al. [31,32]:
CMAX Port: Unb: ¼ f u  CMAX þ
ðka  D  FaÞ
Qh
 
where fu is the fraction unbound in plasma, ka is the absorption rate
constant (set here to 0.1 min1), D is dose in nanomol, Fa is fractionTable 1
Due to its size, Table 1 is attached in a separate ﬁle.
Gene symbols Function TaqMan1 Assay ID 
ABCA1 Transporter (GOI) Hs01059118_m1 
ABCA2 Transporter (GOI) Hs00242232_m1 
ABCA3 Transporter (GOI) Hs00975530_m1 
ABCB1 Transporter (GOI) Hs00184500_m1 
ABCB11 Transporter (GOI) Hs00184824_m1 
ABCB4 Transporter (GOI) Hs00240956_m1 
ABCB5 Transporter (GOI) Hs00698751_m1 
ABCB6 Transporter (GOI) Hs01039213_m1 
ABCB7 Transporter (GOI) Hs00188776_m1 
ABCC1 Transporter (GOI) Hs00219905_m1 
ABCC10 Transporter (GOI) Hs00375701_m1 
ABCC11 Transporter (GOI) Hs01090768_m1 
ABCC12 Transporter (GOI) Hs00264354_m1 
ABCC2 Transporter (GOI) Hs00166123_m1 
ABCC3 Transporter (GOI) Hs00358656_m1 
ABCC4 Transporter (GOI) Hs00988734_m1 
ABCC5 Transporter (GOI) Hs00981087_m1 
ABCC6 Transporter (GOI) Hs01081201_m1 
ABCC8 Transporter (GOI) Hs01093761_m1 
ABCC9 Transporter (GOI) Hs00245832_m1 
ABCD1 Transporter (GOI) Hs00163610_m1 
ABCD3 Transporter (GOI) Hs00161065_m1 
ABCG2 Transporter (GOI) Hs01053790_m1 
ABCG8 Transporter (GOI) Hs00223690_m1 
ATP7A Transporter (GOI) Hs00163707_m1 
ATP7B Transporter (GOI) Hs00163739_m1 
SLC10A1 Transporter (GOI) Hs00161820_m1 
SLC10A2 Transporter (GOI) Hs01001557_m1 
SLC13A1 Transporter (GOI) Hs00223704_m1 
SLC15A1 Transporter (GOI) Hs00953898_m1 
SLC15A2 Transporter (GOI) Hs00221539_m1 
SLC16A1 Transporter (GOI) Hs00161826_m1 
SLC16A10 Transporter (GOI) Hs01039921_m1 
SLC16A2 Transporter (GOI) Hs00185140_m1 
SLC16A3 Transporter (GOI) Hs00358829_m1 
SLC19A1 Transporter (GOI) Hs00953342_m1 
SLC19A2 Transporter (GOI) Hs00949693_m1 
SLC19A3 Transporter (GOI) Hs00228858_m1 
SLC22A1 Transporter (GOI) Hs00427552_m1 
SLC22A11 Transporter (GOI) Hs00218486_m1 
SLC22A12 Transporter (GOI) Hs00375985_m1 
SLC22A14 Transporter (GOI) Hs00899722_m1 
SLC22A2 Transporter (GOI) Hs01010723_m1 
SLC22A3 Transporter (GOI) Hs01009568_m1 
SLC22A4 Transporter (GOI) Hs00268200_m1 
SLC22A5 Transporter (GOI) Hs00929869_m1 
SLC22A6 Transporter (GOI) Hs00537914_m1 
SLC22A7 Transporter (GOI) Hs00198527_m1 
SLC22A8 Transporter (GOI) Hs01056647_m1 
SLC22A9 Transporter (GOI) Hs00971064_m1 
SLC25A13 Transporter (GOI) Hs00185185_m1 
SLC25A27 Transporter (GOI) Hs00188687_m1 
SLC28A1 Transporter (GOI) Hs00984403_m1 
SLC28A2 Transporter (GOI) Hs00188407_m1 absorbed from the gut into the portal vein (set here to 0.99) and Qh
is hepatic blood ﬂow (set here to 1610 ml/min).
2.5. Analyses of gene expression
Copy DNA was synthesized from 1 mg total RNA using
SuperScript1 II Reverse Transcriptase (Invitrogen, Life Technolo-
gy). Random hexanucleotide primers (0.1 A260 U) were added to
the RNA and incubated for 10 min at 70 8C. The samples were left to
cool down to room temperature. Fifty units of reverse transcrip-
tase, 20 units of recombinant human placenta RNase inhibitor,
50 mM dNTPs and 50 mM DTT were added. The reverse transcrip-
tion was carried out for 1 h at 42 8C. The resulting cDNA was
diluted 1:5 and used for RT-qPCR measurements.
Gene expression analyses were performed using customized
TaqMan1 Array microﬂuidic cards (Life Technologies) designed toRelative expression [transcripts/transcript TBP]
Liver Hepatocytes HEK-OCT1 HEK-pcDNA5
42.2 30.4 0.0 0.0
0.9 3.7 0.2 0.2
0.7 0.2 0.7 0.9
13.2 18.8 0.7 0.9
1.0 28.7 0.0 0.0
39.0 32.7 0.0 0.0
0.0 0.0 0.0 0.0
1.3 7.9 0.2 0.2
7.3 11.3 2.1 2.4
0.5 0.0 0.3 0.3
1.8 1.0 0.4 0.6
0.5 1.3 0.0 0.0
0.0 0.0 0.0 0.0
1.9 37.2 0.0 0.0
8.0 14.5 0.0 0.0
0.8 0.5 1.2 1.1
1.4 0.4 0.5 0.6
1.2 7.0 0.0 0.0
0.0 0.0 0.0 0.0
0.7 6.5 0.0 0.0
0.1 0.1 0.0 0.0
4.4 11.8 0.8 0.9
2.5 4.2 0.1 0.1
6.0 35.1 0.0 0.0
0.0 0.0 0.0 0.0
2.6 9.9 0.8 0.8
2.0 124.0 0.0 0.0
0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0
0.6 11.7 0.0 0.0
0.1 0.0 0.0 0.0
9.1 13.7 3.9 4.4
6.7 12.8 0.9 1.1
0.9 17.5 0.2 0.1
0.9 0.0 0.0 0.0
1.0 0.4 1.8 1.9
2.6 13.2 0.6 0.9
17.0 16.4 0.1 0.1
68.5 522.8 79.3 0.0
0.1 0.0 0.0 0.0
0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0
0.0 0.0 0.0 0.0
5.7 28.6 0.0 0.0
0.1 0.0 0.0 0.0
2.5 2.2 0.6 0.6
0.0 0.0 0.0 0.0
2.8 25.0 0.0 0.0
0.0 0.0 0.0 0.0
0.9 12.0 0.0 0.0
9.8 24.2 1.6 2.7
0.4 2.7 0.1 0.2
3.8 6.9 0.0 0.0
0.0 0.0 0.0 0.0
Table 1 (Continued )
Gene symbols Function TaqMan1 Assay ID Relative expression [transcripts/transcript TBP]
Liver Hepatocytes HEK-OCT1 HEK-pcDNA5
SLC28A3 Transporter (GOI) Hs00910439_m1 0.1 0.0 0.0 0.0
SLC29A1 Transporter (GOI) Hs01085706_m1 15.6 33.0 5.0 5.0
SLC29A2 Transporter (GOI) Hs00155426_m1 0.1 0.2 0.2 0.2
SLC29A3 Transporter (GOI) Hs00983219_m1 4.0 9.4 0.2 0.2
SLC29A4 Transporter (GOI) Hs00928283_m1 1.8 2.7 0.2 0.1
SLC2A1 Transporter (GOI) Hs00892681_m1 0.3 1.4 2.9 3.6
SLC2A2 Transporter (GOI) Hs01096904_m1 23.7 478.6 0.0 0.0
SLC2A3 Transporter (GOI) Hs00359840_m1 2.5 0.6 0.1 0.2
SLC31A1 Transporter (GOI) Hs00977268_g1 42.5 75.6 1.5 1.9
SLC38A2 Transporter (GOI) Hs01089954_m1 19.4 8.3 0.9 0.9
SLC38A5 Transporter (GOI) Hs01012028_m1 0.0 0.1 0.0 0.0
SLC3A1 Transporter (GOI) Hs00165789_m1 0.0 0.9 0.0 0.0
SLC3A2 Transporter (GOI) Hs00374243_m1 17.3 17.2 3.4 3.9
SLC47A1 Transporter (GOI) Hs00217320_m1 3.5 22.5 0.2 0.2
SLC47A2 Transporter (GOI) Hs00398719_m1 0.0 0.0 0.0 0.0
SLC5A1 Transporter (GOI) Hs01573790_m1 0.1 0.0 0.0 0.0
SLC5A4 Transporter (GOI) Hs00429526_m1 0.1 0.0 0.0 0.0
SLC6A2 Transporter (GOI) Hs01567442_m1 0.0 0.0 0.0 0.0
SLC6A3 Transporter (GOI) Hs00997364_m1 0.0 0.0 0.0 0.0
SLC6A4 Transporter (GOI) Hs00984355_g1 0.0 0.0 0.0 0.0
SLC6A6 Transporter (GOI) Hs00161778_m1 1.2 0.1 0.4 0.5
SLC7A11 Transporter (GOI) Hs00204928_m1 0.1 0.0 0.3 0.3
SLC7A5 Transporter (GOI) Hs00185826_m1 0.5 0.0 0.8 0.8
SLC7A6 Transporter (GOI) Hs00938056_m1 2.6 0.3 0.9 1.3
SLC7A7 Transporter (GOI) Hs00909952_m1 0.3 0.0 0.0 0.0
SLC7A8 Transporter (GOI) Hs00794796_m1 1.8 0.5 0.4 0.4
SLC7A9 Transporter (GOI) Hs00943195_m1 1.1 4.2 0.0 0.0
SLCO1A2 Transporter (GOI) Hs00366488_m1 0.0 0.0 0.0 0.0
SLCO1B1 Transporter (GOI) Hs00272374_m1 37.7 97.9 0.0 0.0
SLCO1B3 Transporter (GOI) Hs00251986_m1 1.3 62.8 0.0 0.0
SLCO2A1 Transporter (GOI) Hs00194554_m1 0.4 0.0 0.0 0.0
SLCO2B1 Transporter (GOI) Hs00200670_m1 0.2 1.0 0.0 0.0
SLCO3A1 Transporter (GOI) Hs00203184_m1 0.6 0.1 0.1 0.1
SLCO4A1 Transporter (GOI) Hs00249583_m1 1.1 0.0 0.4 0.4
SLCO4C1 Transporter (GOI) Hs00698884_m1 0.6 6.3 0.1 0.1
SLCO5A1 Transporter (GOI) Hs00229597_m1 0.0 0.1 0.2 0.3
SLCO6A1 Transporter (GOI) Hs00542846_m1 0.0 0.0 0.0 0.0
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analyses were performed according to the manufacturer’s instruc-
tions. Brieﬂy, 20 ml cDNA (corresponding to 200 ng of the starting
RNA) was mixed with 80 ml H2O and 100 ml TaqMan Universal PCR
Master Mix (Life Technologies). The mixture was pipetted into two
wells of the microﬂuidic card (100 ml each, 4 samples per card).
The cards were centrifuged at 331  g for 1 min and sealed. The
qPCR was performed using 7900HT Fast Real-Time PCR System
(Life Technologies) under the following conditions: 50 8C for 2 min,
94.5 8C for 10 min and 40 cycles of 97 8C for 30 s and 59.7 8C for
1 min. The data was analysed using SDS version 2.4 and RQ-
manager version 1.2.1 (both from Life Technologies). The expres-
sion of PMAT (SLC29A4) was analysed using a single pre-designed
TaqMan1 gene expression assay (assay ID Hs00928283_m1, Life
Technologies) according to the manufacturer’s instructions.
2.6. Clinical study
Twenty-ﬁve healthy Caucasian volunteers of German descent
were enrolled in the study. Each had at least one active CYP2D6 allele.
The mean age was 30.2 years (range: 19–60 years) and the mean
body mass index was 23.3 kg/m2 (range: 19.4–31 kg/m2). The study
protocol has been described before [8]. Brieﬂy, a single oral dose of
30 mg codeine (Codeine Phosphoricum, Berlin-Chemie, Berlin,
Germany) was administrated with tap water. No food was allowed
for 12 h before and 4 h after drug administration. Alcohol and
grapefruit juice were not allowed for 3 days before, and no additional
medication was allowed for 14 days before administration. Blood
sampling for pharmacokinetic analyses was performed before and
0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after administration of codeine.Urine was collected from 0 to 12 h after codeine administration. The
study protocol was approved by the ethics committee of Humboldt
University (Berlin, Germany). All volunteers gave their written
informed consent before they were enrolled into the study.
2.7. Drug concentration measurement and pharmacokinetic analyses
Plasma and urine concentrations of morphine and codeine were
analysed using high-performance liquid chromatography coupled
with mass spectrometry as described before [8]. Basic pharmacoki-
netic parameters were estimated by non-compartmental analyses
using WinNonlin 2.1 (Pharsight Corp., Mountain View, CA, USA).
2.8. Genetic analyses
In the OCT1 gene the following common loss-of-function
polymorphisms were genotyped: Arg61Cys (rs12208357), Cys88Arg
(rs55918055), Gly401Ser (rs34130495), Gly465Arg (rs34130495),
and a deletion of Met420 (rs72552763). In the CYP2D6 gene the
following alleles were determined: alleles *1, *2, *3, *4, *5, *6, *9,
*10, *35, *41 and duplication of alleles *1, *2 and *4 (the allele
nomenclature is according to http://www.imm.ki.se/CYPalleles/).
The genotyping was performed using single-base primer extension
coupled with capillary electrophoresis with ﬂuorescence detection
as described previously for OCT1 [27] and CYP2D6 [8].
2.9. Statistical analyses
Parametric tests were used to analyze the in vitro data. Two
group comparisons were performed using the Student’s t-test.
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followed by Fisher’s least signiﬁcant difference (LSD) test for
post-hoc pair-wise comparisons.
Nonparametric tests were used to analyze the clinical data. Two-
group comparisons were performed using the Mann–Whitney U
test. Three group comparisons were performed using the Jonc-
kheere-Terpstra trend test. A linear regression model was used to
analyze the combined effects of OCT1 and CYP2D6 genotypes on the
pharmacokinetics of morphine and codeine. OCT1 genotype was
represented as number of active OCT1 alleles. The OCT1 allele *1 was
regarded as active and alleles *2 to *6 as inactive. CYP2D6 genotype
was represented according to the semi-quantitative CYP2D6 gene
dose system of Steimer et al. [33]. According to this scoring system,
we assigned an activity score of 1 to the CYP2D6 alleles *1, *2, and
*35, a score of 0.5 to the reduced activity alleles *9, *10, and *41, and a
score of 0 to the inactive alleles *3, *4, *5, and *6. The score of each
individual was calculated as a sum of the scores of his alleles. In the
case of allele duplication, the allele score was multiplied by two. All
statistical analyses were performed using SPSS Statistics version 19
(SPSS Inc., IBM, Chicago, USA).
3. Results
3.1. Transporter-independent membrane permeability of morphine
and codeine
Both morphine and codeine are weak bases and may penetrate
cell membranes in a transporter-independent manner via passive
diffusion of their non-charged forms. We measured the transport-
er-independent membrane permeability of morphine and codeine
using parallel artiﬁcial membrane permeability assays (PAMPA).
Morphine showed low (Pe of 0.5  0.05  106) and codeine showed
high (Pe of 8.2  0.4  106 cm/s) transporter-independent mem-
brane permeability (Fig. 1). These PAMPA data suggest that morphine,
but not codeine, may depend on carrier-mediated transport for its
cellular uptake.
3.2. Morphine and codeine as inhibitors and substrates of OCT1
First, we measured the ability of morphine and codeine to
inhibit OCT1-mediated cellular uptake. We used increasing
concentrations of morphine and codeine to inhibit the uptake ofFig. 1. Transporter-independent membrane permeability of morphine and codeine
Transporter-independent membrane permeability was measured using parallel
artiﬁcial membrane assays (PAMPA). The membrane permeabilities (Pe) were
calculated as the average of all ﬁve concentrations tested. The data represent mean
values and standard errors of three independent experiments performed in
triplicate.1-methyl-4-phenylpyridinium (MPP+), a model substrate of OCT1,
in OCT1-overexpressing HEK293 cells. Both morphine and codeine
strongly inhibited MPP+ uptake. Morphine was a more potent OCT1
inhibitor than codeine was (IC50 of 4.2  0.6 and 10.5  1.3 mM,
respectively, Fig. 2A).
Next, we analysed the ability of OCT1 to mediate the cellular
uptake of morphine and codeine in OCT1-overexpressing HEK293
cells. As expected from the PAMPA data, OCT1-overexpression did
not affect the cellular uptake of codeine (Fig. 2B). In contrast, OCT1
overexpression signiﬁcantly increased the uptake of morphine at
concentrations up to 50 mM (P < 0.03, Student’s t-test; Fig. 2C). At
clinically relevant concentrations, typically 5 to 20 nM [34,35], the
morphine uptake was 3 to 4-fold higher in OCT1-overexpressing
cells compared to control cells (0.027  0.005 compared to
0.009  0.002 pmol/min/mg protein when incubated with 5 nM
morphine and 0.116  0.025 compared to 0.028  0.007 pmol/min/
mg protein when incubated with 20 nM morphine; P = 0.007,
Student’s t-test; Fig. 2C).
In OCT1-overexpressing cells, the uptake of morphine was
apparently the sum of passive diffusion and OCT1-mediated
uptake. Thus, the portion of the morphine uptake mediated by
OCT1 could be calculated by subtracting the uptake in control cells
not expressing OCT1 from the uptake in the OCT1-ovexpressing
cells. The OCT1-mediated uptake showed typical Michaelis-
Menten kinetics with a KM value of 3.4  0.3 mM and a maximum
transport rate (VMAX) of 29.0  2.8 pmol/mg protein/min (Fig. 2D).
The fraction of OCT1-mediated morphine uptake from the total
morphine uptake, the fraction transported, was strongly dependent
on the concentration of morphine used (Fig. 2E). The fraction
transported by OCT1 was only 17.1% at high concentrations, but
above 65% at the clinically relevant nanomolar concentrations of
morphine.
It could be concluded that, in contrast to codeine, morphine is a
high afﬁnity OCT1 substrate and morphine uptake depends
strongly on OCT1 in cells with high OCT1 expression.
3.3. Uptake of morphine in human hepatocytes: the role of organic
cation transporters
We performed inhibition experiments to analyze the role of
organic cation transporters in the uptake of morphine in primary
human hepatocytes. Addition of MPP+ (a competitive inhibitor of
organic cation transporters [36]) resulted in a reduction of
morphine uptake by 58.5  1.4% (Fig. 3A). This suggests that the
majority of the morphine uptake into human hepatocytes is
dependent on organic cation transporters.
We analysed the mRNA expression of organic cation transporters
in primary human hepatocytes and in human liver to identify
transporters, beyond OCT1, that may contribute to morphine uptake
in hepatocytes (Fig. 3B, Table 1). OCT1 was by far the most strongly
expressed organic cation transporter in both human liver and
primary hepatocytes. Other cation transporters expressed in the
primary hepatocytes were OCT3 and MATE1. This data is in
concordance with previous reports analyzing both mRNA [37] and
protein expression [38] of drug transporters in human hepatocytes.
The OCT1 mRNA expression levels were comparible between OCT1-
overexpressing HEK293 cells and the liver (79.3 and 68.5 transcripts
per TBP transcript, respectively, Fig. 3B). Therefore, the kinetics of
OCT1-mediated morphine uptake may be comparable between the
human liver and the OCT1-overexpressing HEK293 cells.
MATE1 mRNA expression was detectable, but MATE1 is
expressed in the canalicular membrane only [39,40] and therefore
cannot contribute to the morphine uptake from blood.
OCT3 was the second-most strongly expressed organic cation
transporter. OCT3 it is known to be localized in the sinusoidal
membrane of human hepatocytes [22] and therefore may
Fig. 2. OCT1 mediated cellular uptake of morphine, but not of codeine. (A) Morphine and codeine as inhibitors of OCT1. The inhibition of OCT1-mediated uptake was measured
by incubating HEK293 cells overexpressing human OCT1 with 5 nM 3H-labeled 1-methyl-4-phenylpyridinium (MPP+) for 2 min in the presence of increasing concentrations
of morphine or codeine. The half maximal inhibitory concentrations (IC50) are shown. (B) Effect of OCT1 overexpression on the cellular uptake of codeine. HEK293 cells
overexpressing OCT1 and control cells transfected with the empty vector (pcDNA5) were incubated for 2 min with increasing concentrations of 14C-codeine. (C) Effect of OCT1
overexpression on the cellular uptake of morphine. HEK293 cells overexpressing OCT1 and control cells transfected with the empty vector (pcDNA5) were incubated for 2 min
with increasing concentrations of morphine in the absence (OCT1) or in the presence (OCT1 + MPP+) of 1 mM MPP+ as an inhibitor of OCT1-mediated uptake. (D)
Concentration dependence of the OCT1-mediated cellular uptake of morphine. OCT1-mediated uptake was calculated by subtracting the uptake in pcDNA5 control cells from
the uptake in the OCT1-overexpressing cells. Maximal uptake rates (VMAX) and Michaelis constant (KM) are shown. (E) The concentration dependence of the fraction of
morphine that is transported by OCT1 (fraction transported). Fraction transported was calculated as the percentage of OCT1-mediated uptake from the total uptake into the
OCT1-overexpressing cells. OCT1-mediated uptake was calculated by subtracting the uptake in pcDNA5 control cells from the uptake in the OCT1 overexpressing cells. All
data in Fig. 2 represent mean values and standard errors of at least three independent experiments.
M.V. Tzvetkov et al. / Biochemical Pharmacology 86 (2013) 666–678 671contribute to the uptake of morphine from sinusoidal blood.
However, the expression of OCT3 in the primary hepatocytes and
in the human liver samples was less than 1/12 of the OCT1
expression (Fig. 3B). Additionally and most importantly, morphine
was a more than 100-fold less potent inhibitor of OCT3 (IC50 of
538 mM, Fig. 3C) than of OCT1 (IC50 of 4.2, Fig. 2A), and OCT3-
overexpression in HEK293 cells did not result in a signiﬁcantincrease of morphine uptake at any of the concentrations tested
(Fig. 3D).
Considering the much higher expression of OCT1 compared to
OCT3, the much lower potency of morphine as an inhibitor of OCT3
than of OCT1, and the lack of measurable morphine uptake by
OCT3, we can conclude that OCT1 remains the best candidate for
transporting morphine into human hepatocytes and may be
Fig. 3. Morphine uptake in primary human hepatocytes and in OCT3-overexpressing HEK293 cells (A) Primary human hepatocytes were incubated for 2 min with 1 mM 14C-
morphine or 5 nM 3H-MPP+ in the absence or in the presence of 500 mM non-radiolabeled MPP+ as an inhibitor of OCT-mediated uptake. The data represent mean values and
standard errors of at least three independent experiments. * denotes signiﬁcant with P < 0.001 in a Student’s t-test. (B) Expression of organic cation and endogenous amine
transporters in the human liver, primary human hepatocytes and HEK293 cell lines used in this study. The transcription is represented as ratio of the number of transcripts of
interest to the TATA-box binding protein (TBP) used as a housekeeping control. The results represent measurement of single samples performed in duplicate. (C) Morphine as
an inhibitor of OCT3-mediated uptake. The inhibition of OCT3-mediated uptake was measured by incubating HEK293 cells overexpressing human OCT3 with 5 nM 3H-labeled
1-methyl-4-phenylpyridinium (MPP+) for 2 min in the presence of increasing concentrations of morphine (closed circles). The open bar represents an inhibition with 1 mM
cold MPP+ that we used as a reference for complete inhibition of the OCT3-mediated uptake. The half maximal inhibitory concentration (IC50) is shown. (D) Effects of OCT3
overexpression on the cellular uptake of morphine. Control HEK293 cells (pcDNA5) and cells overexpressing OCT3 were incubated for 2 min with radiolabeled morphine in
the absence (OCT3) or presence (OCT3 + MPP+) of 1 mM MPP+ as an inhibitor of the OCT-mediated uptake. The data represent mean values and standard errors of three
independent experiments.
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liver.
3.4. Potential drug-drug interaction affecting OCT1-mediated
morphine uptake
Identiﬁcation of OCT1 as a hepatic morphine uptake transporter
may have implications for potential drug-drug interactions. We
analysed drugs commonly co-administered with morphine for
their ability to inhibit OCT1-mediated morphine uptake in HEK293
cells. We focused on drugs positively charged at pH of 7.4 that are
known to interact with OCT1. We studied adjuvants in pain
treatment (amitriptylin, ﬂuoxetine, imipramine and clomipra-
mine); antiemetics given in cancer chemotherapy, or peri- and
postoperatively together with morphine (tropisetron and ondan-
setron); the chemotherapeutic agent irinotecan; and the calcium
channel blocker verapamil, which has been reported to potentiate
morphine analgesia [41]. All drugs completely inhibited the OCT1-
mediated uptake of morphine in a concentration-dependent
manner (Fig. 4). The potency of the drugs as inhibitors varied
between IC50 of 1.2  0.2 mM (ondansetron) to 6.2  1.4 (imipra-
mine). The observed IC50 values for inhibition of morphine uptake
were close to the known IC50 values for inhibition of the uptake of the
model OCT1 substrates MPP+, ASP+ and TEA+ [28,31,36]. We
compared the IC50 values with the estimated unbound maximalportal vein concentration of the inhibitors (CMAX Portal unbound, Table 2).
At these clinically observed concentrations, irinotecan, verapamil and
ondansetron were able to inhibit more than 50% of the OCT1-
mediated morphine uptake in our in vitro model.
3.5. Effects of genetic polymorphisms on cellular uptake of morphine
We analysed whether known loss-of-function polymorphisms
in OCT1 affect the cellular uptake of morphine. We analysed the
ﬁve naturally existing combinations of loss-of-function variants in
Caucasians (OCT1 alleles *2 to *6, Fig. 5A). All the variants were
overexpressed after stable transfection in HEK293 cells. The alleles
*4, *5, and *6 were not able to transport morphine. The alleles *2
and *3 had only very limited transport capacity compared to wild-
type (25 and 14% of the allele *1 activity when incubated with
1 mm morphine, respectively, P < 2  105; Fig. 5B). Compared to
the wild type, both alleles had reduced maximal activity and the
allele *2 had slightly, but not signiﬁcantly decreased afﬁnity
(Table 3).
3.6. Effects of genetic polymorphisms on morphine
pharmacokinetic in humans
Next we analysed the effects of the loss-of-function polymor-
phisms in the OCT1 gene on morphine pharmacokinetics after oral
Fig. 4. Inhibition of morphine uptake by drugs commonly co-administrated with morphine OCT1-overexpressing HEK293 cells were incubated for 2 min with 5 nM 3H-
morphine in the absence or in the presence of increasing concentrations of the inhibitor (black dots). Control HEK293 pcDNA5 cells were also treated with 3H-morphine
without inhibitor to account for the OCT1-independent morphine uptake (white dots). The data represents mean values and standard errors of at least three independent
experiments.
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of codeine varied between 103 and 398 mg  h/l and the AUC of
morphine varied between 4 and 16.6 mg  h/l. The volunteers
were genotyped for the ﬁve common loss-of-function OCT1
polymorphisms and their allele combinations were determined.In accordance with the in vitro data, we classiﬁed OCT1*1 as
active OCT1*2 to *6 as inactive. Fourteen volunteers carried two
active OCT1 alleles, nine volunteers carried one active and one
inactive OCT1 allele, and two volunteers carried two inactive OCT1
alleles.
Fig. 5. Effects of common loss-of-function polymorphisms in OCT1 on the in vitro cellular uptake and on the pharmacokinetics of morphine and codeine in healthy volunteers
(A) Common OCT1 alleles in Caucasians. The changes known to result in loss-of-function OCT1 or in greatly diminished activity are highlighted in gray. (B) In vitro effects of
loss-of-function OCT1 variants on the uptake of morphine. HEK293 cells overexpressing wild-type (black bar) or variant OCT1 (gray bars) and the control cells stably
transfected with the empty expression vector pcDNA5 (white bar) were incubated for 2 min with 1 mM14C-morphine. The data represent mean values and standard errors of
three independent experiments. (C) and D) Effects of loss-of-function genetic polymorphisms in OCT1 on pharmacokinetics of codeine (C) and morphine (D) in healthy
volunteers. The areas under the time concentration curves (AUCs) are shown for codeine (C) and morphine (D). AUCs were analysed for 24 h after codeine administration. The
volunteers that carried two active OCT1 alleles are depicted as black dots. The volunteers carrying zero or one active alleles are depicted as light and dark grey dots,
respectively. OCT1 allele *1 was considered active and alleles *2 to *6 as inactive. Median AUCs for each group are represented as lines. Signiﬁcance was calculated using the
Mann-Whitney U test for non-parametric comparison between the group of two active and the combined group of zero or one active OCT1 allele carriers. (E) Effects of loss-of-
function genetic polymorphisms on the plasma concentration of morphine over time. Shown are the mean and the standard deviation of morphine plasma concentrations for
each time point for the group of two active OCT1 allele carriers (black dots) and the combined group of zero or one active OCT1 allele carriers (grey dots). (F) Combined effects
of OCT1 and CYP2D6 genotypes on the plasma concentrations of morphine. Ultra-rapid CYP2D6 metabolizers (UM) are deﬁned as carriers of duplications of any of the active
CYP2D6 alleles that were not carrying an inactive CYP2D6 allele on their second chromosome (CYP2D6 gene dose score of 2.5 or higher). Extensive CYP2D6 metabolizers (EM)
were deﬁned as carriers of at least one active allele that lacked duplications of CYP2D6 (CYP2D6 gene dose score of 2 or lower).
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not affected by the loss-of-function OCT1 polymorphisms, but the
AUCs of morphine were signiﬁcantly affected (Fig. 5C and D). The
carriers of loss-of-function OCT1 polymorphisms had signiﬁcantly
higher plasma concentrations compared to the non-carriers
(Fig. 5E). Compared to the carriers of two active OCT1 alleles,
the AUCs of morphine were 1.7-fold higher in the carriers of zero
active OCT1 alleles and 1.5-fold higher in the carriers of one active
OCT1 allele (Table 4). Correspondingly, the maximal plasma
concentration showed a strong trend to increase with the number
of loss-of-function OCT1 alleles (Table 4).
We analysed the effect of OCT1 genotypes on adverse effects
after codeine administration. Due to the low dose of codeine used,only mild adverse effects were observed. Out of 25 volunteers, 16
reported light sedation (64%), 6 reported headache (24%), 3
reported dizziness (12%) and one reported nausea (4%). Altogether,
100% of the carriers of loss-of-function OCT1 polymorphisms
showed at least one type of adverse effect compared to 64% of the
non-carriers (P = 0.04, Fisher’s exact test).
We also analysed the combined effects of CYP2D6 and OCT1
genotypes on the pharmacokinetics of morphine. The study used
here was originally designed to analyze the effects of ultra-rapid
CYP2D6 metabolism [8] and therefore the study population was
enriched for carriers of CYP2D6 gene duplications/multiplications
(11 out of 25 in this study compared to 1 out of 25 expected in a
random Caucasian population).
Table 2
Inhibition of OCT1-mediated morphine uptake by drugs commonly co-administered with morphine.
Drug IC50 [mM] Dose CMAX Unb.[mM]
a CMAX Unb/IC50 CMAX Port. Unb. [mM] Inhibition of OCT1-mediated
morphine uptake at CMAX, Port Unb.
Irinotecan 1.5  0.3 240 mg/m2 3.89 2.6 3.9 b 76.40%
Verapamil 1.6  0.3 120 mg 0.06 0.04 1.7 54.30%
Ondansetron (oral) 1.2  0.2 24 mg 0.12 0.1 1.2 52.10%
Ondansetron (i.v.) 1.2  0.2 0.15 mg/kg 0.08 0.06 0.08 b 3.10%
Imipramine 6.2  1.4 200 mg 0.07 0.01 4.5 34.30%
Codeine 10.9  0.8 30 mg 0.11 0.01 4.3 23.60%
Amitriptyline 4.4  1.6 100 mg 0.01 0.002 1 18.50%
Tropisetron 3.3  0.6 5 mg 0.04 0.01 0.3 17.10%
Fluoxetine 6.0  0.3 60 mg 0.01 0.002 0.7 5.90%
Clomipramine 4.6  0.6 50 mg 0.005 0.001 0.4 2.69%
CMAX Unb, maximal plasma concentration of the unbound drug; CMAX Port. Unb., maximal unbound plasma concentration in the portal vein, Table 3. Effects of the common
functional amino acid substitutions in OCT1 on the kinetics of morphine uptake.
a The maximal plasma concentrations (CMAX) and the fraction of unbound drug in plasma (fu), which are required for the calculations, were obtained from Goodman and
Gilman’s The Pharmacological Basis of Therapeutics [49] except for the CMAX of ondansetron (Zofran
1, information for prescribers), tropisetron [50], codeine (Table 4, this
work), ﬂuoxetine [51] and clomipramine[52] and the fu of tropisetron (Navoban
1, information for prescribers) and clomipramine [53].
b In the case of i.v. administration, the CMAX, Port. Unb. was assumed equal to CMAX Unb.
Table 3
Effects of the common functional amino acid substitutions in OCT1 on the kinetics of morphine uptake.
OCT1 allele Characteristic amino
acid substitutions
Vmax [pmol/min/mg protein] KM [mM] CLint (Vmax/KM)
Mean SEM Mean SEM [ml/min/g protein]
OCT1*1 Reference (WT) 29.0 2.7 3.4 0.3 8.7
OCT1*2 420del 7.21** 0.7 5.0+ 1.1 1.4
OCT1*3 61Cys 6.25** 0.9 3.5 1.0 1.8
OCT1*4 401Ser n.a. n.a. n.a. n.a. n.a.
OCT1*5 420del/465Arg n.a. n.a. n.a. n.a. n.a.
OCT1*6 420del/88Arg n.a. n.a. n.a. n.a. n.a.
n.a., not applicable.
** P < 0.001 compared to the WT reference in a Fisher’s least signiﬁcant difference test for post-hoc pair-wise comparisons following one way ANOVA (P < 105).
+ P = 0.09 compared to the WT reference in a Fisher’s least signiﬁcant difference test for post-hoc pair-wise comparisons following one way ANOVA.
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signiﬁcant after adjustment for the effect of CYP2D6 genotypes
(P = 0.035 in multiple regression analyses, Table 4). The
combination of extensive CYP2D6 metabolism and extensive
OCT1 transport (which is the most common combination in the
population and may be regarded as a reference) showed the
lowest morphine plasma concentrations after codeine adminis-
tration (Fig. 5F). Compared with this reference group, theTable 4
Effects of OCT1 genotypes on the pharmacokinetics of morphine and codeine.
Pharmacokinetic parameter Number of active OCT1 allelesa (N) 
two (14) one (9) 
Morphine
Cmax [mg/l] 1.92 (0.90) 2.59 (1.20)
t1/2 [h] 14.4 (6.6) 12.4 (3.0) 
AUC0-24h [mg  h/l] 7.83 (2.8) 12.0 (3.8) 
Ae 0-12h [mg] 50.9 (22.9) 60.5 (27.3) 
CLrenal 8.92 (2.15) 6.63 (1.53)
AUCpolym/AUC
d 1 1.5 
Codeine
Cmax [mg/l] 52.7 (22.1) 44.3 (13.1) 
t1/2 3.70 (0.68) 3.76 (0.24)
AUC0-24h [mg  h/l] 204.3 (75.7) 204.5 (37.8) 
Ae 0-12h [mg] 951 (283) 956 (414) 
CLrenal 5.46 (1.91) 4.91 (1.53)
AUCpolym/AUC 1 1 
a Shown are means (standard deviation) of the listed major pharmacokinetic param
b P value for trend corresponding to number of active OCT1 alleles was calculated u
c Signiﬁcance in a multivariate model including OCT1 and CYP2D6 genotypes as inde
d Ratio between the AUCs of the respective OCT1 genotype group and the group witultra rapid CYP2D6 metabolizers with poor OCT1 transport
capacity (carriers of zero or one active OCT1 alleles) had on
average 1.74-fold higher morphine AUC, while the individuals
with extensive OCT1 transport capacity had on average only 1.2-
fold higher morphine AUC. This data suggests that the risk of
concentration-dependent adverse effects of morphine in ultra-
rapid CYP2D6 metabolizers may be strongly dependent on their
OCT1 genotypes.Pb PCYP2D6-adjusted
c
zero (2)
 2.63 (0.04) 0.06 0.3
12.9 (1.4) 0.8 0.4
13.3 (3.5) 0.007 0.03
80.2 (8.3) 0.15 0.5
 8.40 (1.43) 0.20 0.1
1.7
43.4 (0.3) 0.4 0.8
 3.84 (0.37) 0.2 0.4
194.9 (21.3) 0.6 0.6
567 (29.6) 0.43 0.1
 3.23 (0.53) 0.18 0.1
1
eters.
sing Jonckheere-Terpstra trend test.
pendent variables.
h two active OCT1 alleles.
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We have demonstrated that morphine is a high afﬁnity
substrate of OCT1. Both the in vitro and the in vivo data strongly
suggest that OCT1 mediates morphine uptake into hepatocytes and
that lack of OCT1 activity results in signiﬁcantly higher morphine
plasma concentrations after codeine administration.
In contrast to morphine, codeine was highly membrane
permeable and its cellular uptake and plasma concentrations
did not depend on OCT1. Codeine inhibited, but apparently was not
transported by, OCT1 (Fig. 2A and B). One explanation may be that
codeine is an inhibitor, but not a substrate of OCT1. An alternative
and more probable explanation is that the high membrane
permeability of codeine dominates its uptake. The membrane
permeability of codeine was 16-fold higher than that of morphine
in the PAMPA assays (Fig. 1) and 6-fold higher in the control
HEK293 cells (Fig. 2B). Therefore, although OCT1-mediated uptake
may still exist, it was difﬁcult to detect and of no relevance for the
pharmacokinetics of codeine. Still, our data suggests that OCT1
genotypes may play a role in the case of codeine administration by
affecting the plasma concentrations of codeine’s active metabolite,
morphine.
Based on our data, a model for the involvement of OCT1 in
codeine pharmacokinetics may be suggested (Fig. 6). Codeine is
highly membrane permeable and enters the hepatocytes by
gradient-driven diffusion. The majority of the codeine is glucur-
onidated and eliminated, but a small part is metabolized to
morphine by CYP2D6. The majority of the morphine will be also
glucuronidated, but a small part of the morphine will leave the
hepatocyte to execute its antinociceptive activity. The morphine
may leave the hepatocytes either by diffusion, or with the help of
efﬂux transporters. The diffusion process may play an important
role in the early stages of codeine to morphine transformation,
where the extracellular concentration of morphine is close to zero.
There are some indications that MRP3 may transport morphine out
of the hepatocytes [42], but also other transporters may be
involved. Based on our data we may add to this model that the
extracellular morphine may be transported back into the
hepatocytes by OCT1. Therefore lack of OCT1 activity (due to
loss-of-function polymorphisms or competitive inhibition by other
co-administrated drugs) may lead to higher plasma concentrations
of morphine after codeine administration.Fig. 6. A model for the role of OCT1 and CYP2D6 in the hepatic uptake and
metabolism of morphine after codeine administration Open arrows represent the
process of transporter-independent diffusion through the cell membrane.A direct consequence of our ﬁndings is that carriers of loss-of-
function OCT1 polymorphisms may have better analgesic effects
from codeine or morphine, but may also be at higher risk of
toxicity. In the carriers of any loss-of-function OCT1 allele, we
observed on average more than 50% higher plasma morphine
concentrations compared to carriers of two completely active OCT1
alleles (Fig. 5). The size of this effect is comparable with the effect
of the CYP2D6 gene duplication [8]. Although in the clinical practice
the dose of morphine and other opioids is usually adjusted until
the pain of patients is correctly treated, OCT1 genotyping may be
considered relevant to personalize the starting dose of morphine
(e.g. peri- and postoperatively) and shorten the time required for
adjustment.
Ultra-rapid CYP2D6 metabolism may result in severe morphine
toxicity after codeine administration [9–13], but not every CYP2D6
ultra-rapid metabolizer is at high risk [10,16]. Our data shows that
the carriers of loss-of-function OCT1 variants within the group of
ultra-rapid CYP2D6 metabolizers had especially high morphine
concentrations. Poor OCT1 transport results in reduced reuptake
and metabolism that further increases morphine plasma concen-
trations in ultra-rapid CYP2D6 metabolizers (Fig. 5). Considering
the 2% frequency of ultra-rapid metabolizers in Caucasians [43],
one in every 100 Caucasian patients will carry the high risk
combination of ultra-rapid CYP2D6 metabolizing capacity and
poor OCT1 transporter capacity.
OCT1 polymorphisms should have similar effects after direct
morphine administration. In this case, CYP2D6 genotype does not
play a major role and all carriers of loss-of-function OCT1
polymorphisms, or close to 50% of Caucasians, are expected to
have increased morphine plasma concentrations. Morphine has
an intensive ﬁrst pass effect and the production of hepatic
metabolites is higher after oral than after i.v. administration [44].
Therefore, it may be expected that the effects of OCT1 polymor-
phisms will be more pronounced after oral than after i.v.
morphine administration.
OCT1 polymorphisms may affect the pharmacokinetics of
other opioids beyond morphine and its pro-drug codeine, as
we previously reported for O-desmethyltramadol, the active
metabolite of tramadol [27]. Consequently, carriers of loss-of-
function OCT1 polymorphisms may be at increased risk of adverse
effects not only after codeine or morphine, but also after tramadol
administration. It remains to be clariﬁed whether the pharmaco-
kinetics of other opioids may be affected by OCT1 polymorphisms.
Our data suggests that OCT1 affects the hepatocellular uptake
only of drugs or active metabolites with low membrane
permeability (morphine and O-desmethyltramadol), but not with
high membrane permeability (codeine and tramadol; [27] and
this study). Therefore the pharmacokinetics of high permeability
opioids like fentanyl or oxycodone are not expected to depend on
OCT1.
Another consequence of the OCT1-mediated hepatocellular
uptake of morphine is the potential for drug-drug interactions. Our
in vitro data suggests that irinotecan and ondansetron may inhibit
OCT1-mediated morphine uptake at clinically relevant concentra-
tions (Table 2). Irinotecan and morphine co-administration in
advanced colorectal cancer is not unlikely. Ondansetron may reach
concentrations inhibiting OCT1-mediated morphine uptake only
when given orally, e.g. to treat chemotherapy- or radiotherapy-
induced nausea and vomiting (Table 2).
The plasma concentrations of the potential OCT1 inhibitors are
generally too low to cause relevant inhibition, with the possible
exception of irinotecan (Table 2). However, if we account for the
fact that much higher concentrations may be reached in the
hepatic vein after oral administration [45] all eight drugs tested
can be regarded to have the potential for drug-drug interactions
(CMAX Port. Unb./IC50 > 0.1) [46].
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may inhibit OCT1-mediated drug uptake to only a minor extent.
The maximal unbound portal vein concentrations after oral
administration of morphine or codeine are about twofold below
the corresponding IC50 for both drugs and may lead to only limited
OCT1 inhibition.
Interestingly, our in vitro data will suggest that under the
condition of this study the portal vein concentration of codeine
may be sufﬁcient to inhibit the uptake of its metabolite morphine
by up to 24% (Table 2). These drug-drug interactions are expected
to affect only the carriers of at least one active OCT1 allele.
Therefore, the effects of OCT1 polymorphisms on morphine plasma
concentrations may be more pronounced when morphine and not
codeine is administrated.
Morphine uptake in the liver is a combination of transporter-
independent diffusion and OCT1-dependent transport (Fig. 2C).
The diffusion increases linearly with morphine concentration,
while OCT1-mediated uptake is saturable. Therefore, diffusion
will play a dominant role at high drug concentration, and the
OCT1-mediated transported will predominate at low drug
concentration. Typical in vivo morphine concentrations are in
the nanomolar range [34,35], which is much below the KM of
OCT1 for morphine (3.4 mM, Fig. 2D). In this case the morphine
fraction transported by OCT1 will be 60 to 80% (Figs. 2E and 3A).
Therefore even a complete lack of OCT1 activity will not fully
prevent morphine from entering hepatocytes. This may be seen
in the effects of both loss-of-function OCT1 polymorphisms
(Fig. 5B) and drug inhibition (Fig. 4). In both cases the maximally
reduced uptake was not zero, but equal to the uptake of the
control cells.
It has been previously reported that OCT1 is expressed in brain
micro-vascular endothelial cells and may contribute to the
transport of lamotrigine through the blood-brain barrier [47,48].
According to our ﬁndings OCT1 may also contribute to the
penetration of morphine through the blood-brain barrier. Howev-
er, the expression of OCT1 at the blood-brain barrier is much
weaker than in the liver, and other OCT transporters like OCT2 may
also be involved [48]. Therefore, the relevance of OCT1 for the
distribution of morphine in the brain requires further investiga-
tion, and the effects of OCT1 polymorphisms on response to
morphine may be complex.
Our clinical study has some limitations that should be
considered. First, the observed effects of OCT1 polymorphisms
on morphine pharmacokinetics were based on only 25 individ-
uals. However, the results were highly statistically signiﬁcant
and in complete concordance with the in vitro data. Second,
the study population was enriched for ultra-rapid CYP2D6
metabolizers. This may lead to an overestimation of the effect
size of loss of OCT1 activity in the general population, but it may
be indeed that the OCT1 genotype plays a particular role in
codeine treatment in ultra-rapid CYP2D6 metabolizers. Third,
the study was neither designed nor sufﬁciently powered to
conclusively analyze pharmacodynamic endpoints or adverse
effects. Nevertheless, it was interesting to note that there were
more adverse effects in those patients with low-activity OCT1
genotypes.
In conclusion, morphine is a drug with weak basic chemical
properties that is transported by the organic cation transporter
OCT1. This was extensively experimentally conﬁrmed using a
series of model systems. A study in healthy volunteers showed that
loss of OCT1 activity may be relevant for morphine pharmacoki-
netics in humans. Further larger studies on patients receiving
morphine in real clinical settings should be considered for an
evidence-based decision regarding whether or not the OCT1
genotype and drug-drug interactions with OCT1 are clinically
relevant and should be included in treatment guidelines.Acknowledgments
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